Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Masaru Katoh, Simona Tavolari
FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (GAs) in tumor tissues or circulating tumor DNAs, without concomitant assessment of FGFR2 signalling status. Accordingly, we performed multi-omic analyses of FGFR2 genes and FGFR2 signalling molecules in the tissue samples from 36 iCCA naïve patients. Gain-of-function FGFR2 GAs were detected in 7 patients, including missense mutations (n = 3; p...
February 7, 2024: Scientific Reports